Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Cadila Healthcare

    Tag: Cadila Healthcare

    You Searched For "Cadila Healthcare"
    Cadila Healthcare Moraiya plant gets USFDA warning letter for significant violations of CGMP

    Cadila Healthcare Moraiya plant gets USFDA warning letter for significant violations of CGMP

    Medical Dialogues Bureau16 Nov 2019 5:41 AM GMT
    Cadila Healthcare failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and/or sterilise equipment and utensils at...
    NPPA fixes retail price of 14 drug formulations; Details

    NPPA fixes retail price of 14 drug formulations; Details

    Farhat Nasim13 Nov 2019 5:53 AM GMT
    New Delhi: Through a recent notification, the apex drug price regulatory agency, the National Pharmaceutical Pricing Authority (NPPA) has fixed the...
    New USFDA warning letters show Glenmark, Lupin, Cadila Healthcare in trouble

    New USFDA warning letters show Glenmark, Lupin, Cadila Healthcare in trouble

    Medical Dialogues Bureau7 Nov 2019 10:50 AM GMT
    Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd. and Lupin Ltd. are the latest local medicine makers to be reprimanded by the US Food and Drug...
    Cadila Healthcare gets EIR from USFDA for Baddi facility

    Cadila Healthcare gets EIR from USFDA for Baddi facility

    Medical Dialogues Bureau1 Nov 2019 8:41 AM GMT
    New Delhi: Drug firm Cadila Healthcare on Thursday said its Baddi facility in Himachal Pradesh has received establishment inspection report (EIR) from...
    Cadila Healthcare arm gets USFDA nod for Haloperidol Decanoate injection to treat schizophrenia

    Cadila Healthcare arm gets USFDA nod for Haloperidol Decanoate injection to treat schizophrenia

    Medical Dialogues Bureau25 Oct 2019 6:02 AM GMT
    Haloperidol is used in the treatment of schizophrenia and for the control of tics and vocal utterances of Tourette syndrome, Cadila Healthcare...
    Cadila Healthcare largest API manufacturing site clears USFDA inspection

    Cadila Healthcare largest API manufacturing site clears USFDA inspection

    Medical Dialogues Bureau12 Oct 2019 6:11 AM GMT
    The US Food and Drug Administration (USFDA) inspected the company's active pharmaceutical ingredients (API) manufacturing facility at Dabhasa from...
    Cadila Healthcare to sell right of cholesterol-lowering drug Zypitamag for Rs 49 crore

    Cadila Healthcare to sell right of cholesterol-lowering drug Zypitamag for Rs 49 crore

    Farhat Nasim1 Oct 2019 8:43 AM GMT
    The company has entered into an asset purchase agreement to sell its right, title and interest in Zypitamag, along with applicable registrations and...
    NPPA fixes retail price of 10 combo drugs including Metformin, Rosuvastatin; Details

    NPPA fixes retail price of 10 combo drugs including Metformin, Rosuvastatin; Details

    Farhat Nasim16 Aug 2019 10:31 AM GMT
    New Delhi: Through a recent notification, the apex drug price regulatory agency, the National Pharmaceutical Pricing Authority (NPPA) has fixed the...
    Cadila Healthcare gets OAI letter from USFDA for Moraiya facility

    Cadila Healthcare gets OAI letter from USFDA for Moraiya facility

    Medical Dialogues Bureau8 Aug 2019 4:30 AM GMT
    The company has received a letter from the USFDA classifying the inspection conducted at its Moraiya facility from April 22 to May 3 as OAI, Cadila...
    Zydus Cadila completes phase III trial of Diabetes drug Lipaglyn in India

    Zydus Cadila completes phase III trial of Diabetes drug Lipaglyn in India

    Medical Dialogues Bureau5 Aug 2019 4:30 AM GMT
    Saroglitazar Magnesium was launched in India during September 2013, under the brand name 'Lipaglyn', for the treatment of hypertriglyceridemia and...
    Cadila Healthcare Ankleshwar facility successfully completes USFDA inspection

    Cadila Healthcare Ankleshwar facility successfully completes USFDA inspection

    Medical Dialogues Bureau1 Aug 2019 3:55 AM GMT
    "The United States Food and Drug Administration (USFDA) inspected the company's active pharmaceutical ingredient manufacturing facility located at...
    Zydus Cadila launches Ramelteon tablets in US to treat insomnia

    Zydus Cadila launches Ramelteon tablets in US to treat insomnia

    Medical Dialogues Bureau25 July 2019 5:53 AM GMT
    In a BSE filing, Zydus Cadila announced the "launch of Ramelteon tablets, 8 mg upon receiving the final approval from the USFDA. Ramelteon is a...
    Next

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier

    This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:

    Search only trustworthy HONcode health websites:

    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

    © 2020 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    X